How to Get AndroGel in Arizona: Prescription, Telehealth, and Pharmacy Guide

At a glance
- Drug / AndroGel (testosterone gel 1% and 1.62%), Schedule III controlled substance
- Manufacturer / AbbVie
- Indication / male hypogonadism (confirmed low serum testosterone)
- Telehealth prescribing in AZ / Yes, permitted under Arizona telemedicine law
- Compounding alternative / Yes, via licensed 503A compounding pharmacies in AZ
- Arizona Medicaid coverage / Not covered for male hypogonadism
- Typical time to first dose / 5 to 10 business days from initial consult
- Key labs before starting / Total testosterone (AM), free testosterone, LH, FSH, hematocrit, PSA
- Prescribers allowed / MD, DO, NP (with collaborative agreement or independent practice), PA
- Controlled substance schedule / DEA Schedule III
What Is AndroGel and Why Arizona Patients Need a Clear Access Path
AndroGel is a hydroalcoholic testosterone gel applied to the skin once daily. AbbVie markets two concentrations: 1% (delivering 25 mg or 50 mg of testosterone per application) and 1.62% (delivering 20.25 mg to 81 mg per application). The FDA approved the 1% formulation in 2000 and the 1.62% formulation in 2011 for adult male hypogonadism, defined as a clinical syndrome of low serum testosterone combined with signs and symptoms such as reduced libido, fatigue, loss of muscle mass, and mood disturbance. FDA AndroGel labeling.
The Condition AndroGel Treats
Male hypogonadism affects roughly 2.1% to 3.8% of men aged 40 to 79, according to data from the European Male Ageing Study published in the New England Journal of Medicine [1]. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials (N=788 men aged 65 and older with serum testosterone <275 ng/dL), demonstrated that testosterone treatment improved sexual function, physical capacity, and bone mineral density over 12 months [2]. Those findings, published in NEJM in 2016, remain the most cited evidence base for testosterone therapy in older men.
Arizona-Specific Access Challenges
Arizona does not place additional scheduling restrictions on testosterone beyond the federal DEA Schedule III classification. The state does not require a triplicate prescription form. Arizona Medicaid (AHCCCS) does not cover AndroGel for male hypogonadism, so most patients pay cash or rely on commercial insurance. Cash prices for a 30-day supply of AndroGel 1.62% range from approximately $400 to $600 at retail pharmacies without manufacturer coupon assistance [3].
Step 1: Confirm You Have Low Testosterone With the Right Labs
Which Labs Are Required
Before any prescriber in Arizona can legally write for AndroGel, you need a documented low serum testosterone. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism specifies that diagnosis requires two separate morning total testosterone measurements below the normal reference range, typically below 300 ng/dL, on two different days [4]. A single low value is not sufficient for diagnosis or for insurance prior authorization.
The standard pre-treatment lab panel includes:
- Total testosterone (drawn between 7 AM and 10 AM, when levels peak)
- Free testosterone (calculated or by equilibrium dialysis)
- Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to classify primary vs. Secondary hypogonadism
- Hematocrit or complete blood count (testosterone raises red cell mass)
- Prostate-specific antigen (PSA) in men aged 40 and older
- Sex hormone-binding globulin (SHBG), which affects free testosterone calculation
The Endocrine Society guideline states: "We recommend measurement of morning total testosterone as the initial diagnostic test for androgen deficiency." [4]
Where to Get Labs in Arizona
Quest Diagnostics and Labcorp both operate dozens of patient service centers across the Phoenix metro, Tucson, Flagstaff, and Yuma areas. Many telehealth platforms serving Arizona generate an electronic lab order that you fulfill at a nearby draw site before your prescriber visit, cutting out the need for a separate primary care appointment. Results typically return within 24 to 48 hours.
Step 2: Choose Your Prescriber, In-Person or Telehealth
In-Person Prescribers in Arizona
Arizona-licensed physicians (MD or DO), nurse practitioners, and physician assistants can all prescribe Schedule III controlled substances including testosterone, provided they hold a valid DEA registration number in Arizona. Endocrinologists and urologists are the most common specialists managing testosterone therapy, but many primary care and men's health clinic providers prescribe it as well. The Arizona Medical Board maintains a public license verification tool where you can confirm a provider's active status before scheduling.
Telehealth Prescribing for AndroGel in Arizona
Arizona permits synchronous audio-visual telehealth prescribing for controlled substances under state law, consistent with the federal Ryan Haight Online Pharmacy Consumer Protection Act. Arizona Revised Statutes § 36-3602 defines telemedicine and authorizes prescribing when a valid provider-patient relationship is established via real-time, two-way audio-video communication [5].
Telehealth is a legal and practical option for AndroGel in Arizona. A licensed telehealth provider must:
- Conduct a synchronous video visit (not audio-only for controlled substances)
- Review your lab results showing confirmed low testosterone
- Perform or review a relevant medical history and symptom assessment
- Issue a prescription to an Arizona-licensed pharmacy
During the federal COVID-19 public health emergency, the DEA granted temporary authority for controlled substance prescribing via telemedicine without an in-person visit. The DEA has extended certain telemedicine flexibilities through at least 2025 while permanent rules are finalized [6]. Arizona residents should confirm with their specific telehealth provider whether those rules apply to their situation.
Who Can Prescribe: MD vs. NP vs. PA
All three provider types can prescribe AndroGel in Arizona, with important distinctions:
- MD/DO: Full independent prescribing authority; no collaboration required.
- NP: Arizona granted NPs full practice authority in 2019 (ARS § 32-1606), so NPs can prescribe Schedule III substances independently with a valid DEA number.
- PA: PAs in Arizona may prescribe controlled substances under a written supervising physician agreement and with their own DEA registration.
Step 3: Understand Prior Authorization If You Have Commercial Insurance
What Insurers Require
Most commercial insurers in Arizona require prior authorization (PA) before covering AndroGel brand name, and many will approve only generic testosterone gel or require step therapy through a less expensive agent first. A typical PA submission must include:
- Two documented morning total testosterone values below the plan's threshold (often below 300 ng/dL)
- Clinical notes documenting signs and symptoms of hypogonadism
- PSA value (most plans require PSA <4.0 ng/mL or a documented urology referral if higher)
- Prescriber attestation that the patient has classic hypogonadism, not age-related decline treated off-label
The Endocrine Society guideline explicitly states the Society "recommends against testosterone therapy in men who have not been reliably diagnosed with hypogonadism." [4] Insurers rely on that language to deny coverage for patients without two confirmatory low values.
Step Therapy and Alternatives
Many Arizona insurance plans require that patients try a lower-cost testosterone formulation, such as generic testosterone gel 1% or testosterone cypionate injection (typically $30 to $60 per month at compounding pharmacies), before approving brand-name AndroGel. If you prefer the branded gel, your prescriber can submit a medical exception citing formulation tolerability or prior trial failure.
The following decision framework summarizes the Arizona prior authorization pathway:
| Step | Action | Typical Timeline | |------|--------|-----------------| | 1 | Two AM testosterone draws on separate days | 3 to 7 days | | 2 | Video or in-person prescriber visit | Same day to 5 days | | 3 | Prescriber submits PA to insurer | 1 to 3 business days | | 4 | Insurer decision (standard review) | Up to 14 business days in AZ | | 5 | Pharmacy dispenses or appeals filed | 1 to 5 additional days |
Arizona statute ARS § 20-3151 requires insurers to complete standard PA decisions within 14 days and urgent decisions within 72 hours [7].
Step 4: Fill the Prescription, Retail, Specialty, and Compounding Pharmacies
Retail Chain Pharmacies
Every major retail chain operating in Arizona (CVS, Walgreens, Fry's/Kroger, Costco, Walmart) can dispense AndroGel and generic testosterone gel. Call ahead to confirm stock; testosterone gel 1.62% is sometimes back-ordered at smaller stores. The AbbVie AndroGel Savings Card reduces the out-of-pocket cost for eligible commercially insured patients to as low as $0 per month on qualified plans (not valid for government programs including Medicaid or Medicare Part D) [3].
Mail-Order and Specialty Pharmacies
Express Scripts, CVS Caremark, and OptumRx are the largest pharmacy benefit managers operating in Arizona. If your plan routes testosterone to specialty pharmacy, expect a first-fill delivery time of 3 to 7 business days after PA approval, with monthly auto-shipment thereafter.
503A Compounding Pharmacies in Arizona
Arizona-licensed 503A compounding pharmacies are permitted to compound testosterone gel for individual patients when a valid prescription exists and a commercially manufactured product does not meet the patient's clinical needs (e.g., specific concentration, base formulation, or documented allergy to an excipient). The FDA distinguishes 503A compounders (patient-specific) from 503B outsourcing facilities (bulk, non-patient-specific) [8].
Compounded testosterone gel in concentrations such as 2%, 5%, or 10% may be significantly less expensive than brand-name AndroGel, often $40 to $120 per month. Compounded products are not FDA-approved and do not undergo the same potency, sterility, and bioequivalence testing as AndroGel. The FDA's guidance on compounding is clear: compounding pharmacies must comply with USP Chapter 795 standards for non-sterile preparations [8].
Arizona residents should verify their compounding pharmacy's license at the Arizona State Board of Pharmacy public lookup tool before using a compounded product.
Monitoring After Starting AndroGel
Follow-Up Labs and Dose Titration
The Endocrine Society recommends checking serum testosterone 3 to 6 months after initiating therapy, then annually once stable, targeting a mid-normal range of 400 to 700 ng/dL [4]. AndroGel 1.62% is typically initiated at 40.5 mg (two pump actuations) applied once daily to the shoulders or upper arms, with dose adjustments at 4 to 6 weeks based on lab response. The maximum approved dose is 81 mg per day.
Hematocrit should be measured at 3 to 6 months and annually; values above 54% require dose reduction or temporary discontinuation to reduce thrombosis risk [4]. PSA should be rechecked at 3 to 6 months and then per age-appropriate prostate cancer screening guidelines from the American Cancer Society [9].
Transfer of Testosterone Monitoring
Men who started AndroGel in another state and moved to Arizona can transfer their prescription to an Arizona pharmacy. Federal law and DEA regulations allow Schedule III prescriptions to be transferred between licensed pharmacies one time (for non-controlled substances, unlimited transfers are allowed). Your prescriber should also establish care with an Arizona provider for ongoing monitoring.
Skin Transfer Risk and Application Instructions
AndroGel carries a black-box warning regarding secondary exposure: testosterone transferred from an adult male user's skin to a female partner or child can cause virilization [3]. Apply the gel to shoulders and upper arms only (for 1.62%), wash hands immediately after application, and cover the application site with clothing before skin-to-skin contact. The FDA added this warning after case reports of virilization in children exposed to testosterone gel through physical contact [8].
Cost Management Strategies for Arizona Patients
Manufacturer Savings Programs
AbbVie's AndroGel patient assistance program (AbbVie myAbbVie Assist) covers patients who meet income eligibility criteria and have no applicable insurance coverage. Eligibility is determined at application and typically requires household income at or below 400% of the federal poverty level.
GoodRx and Cash-Pay Options
GoodRx and similar discount programs can reduce the cash price for generic testosterone gel 1% at Arizona pharmacies to approximately $60 to $120 for a 30-day supply, depending on the pharmacy and specific product [3]. Testosterone gel 1.62% generic cash prices are higher, typically $150 to $300 without a coupon.
Compounding as a Cost Alternative
For patients without insurance coverage, a 503A-compounded testosterone gel at a standard 2% or 5% concentration may be the most cost-effective option. A 100-gram tube of compounded testosterone 2% gel (delivering roughly 20 mg testosterone per gram) from an Arizona compounding pharmacy commonly runs $50 to $90 per month. Confirm the pharmacy uses USP-grade pharmaceutical-grade testosterone as the active ingredient and follows Arizona Board of Pharmacy compounding standards.
Safety Considerations and Contraindications
Who Should Not Use AndroGel
The FDA label for AndroGel lists the following contraindications [3]:
- Males with breast carcinoma or known or suspected prostate carcinoma
- Women (AndroGel is not approved for use in women; serious fetal harm from virilization is possible in pregnant women exposed via skin contact)
- Hypersensitivity to testosterone or any gel component
Testosterone therapy is used with caution in men with severe untreated sleep apnea, heart failure (New York Heart Association Class III or IV), hematocrit above 50%, uncontrolled polycythemia, or active thromboembolic disease. The FDA added a labeling warning in 2014 regarding venous thromboembolism risk [8].
Cardiovascular Evidence
The TRAVERSE trial (N=5,246 men aged 45 to 80 with hypogonadism and elevated cardiovascular risk, published in NEJM 2023) found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months [10]. The trial reported a statistically significant increase in pulmonary embolism and atrial fibrillation in the testosterone group, a finding that reinforces the importance of baseline cardiovascular risk assessment. The hazard ratio for MACE was 0.96 (95% CI 0.83 to 1.12; P<0.001 for non-inferiority) [10].
Prescribers in Arizona should review the TRAVERSE data with patients who have pre-existing cardiovascular risk factors before starting AndroGel.
Frequently asked questions
›How do I get an AndroGel prescription in Arizona?
›What labs are needed before AndroGel in Arizona?
›Are there telehealth providers in Arizona prescribing AndroGel?
›How long until I receive AndroGel in Arizona?
›Can I transfer an AndroGel prescription to Arizona?
›Are 503A pharmacies in Arizona licensed to ship testosterone gel?
›Who can prescribe AndroGel in Arizona, MD vs. NP vs. PA?
›What documentation does prior authorization require in Arizona?
›Does Arizona Medicaid cover AndroGel?
›What is the difference between AndroGel 1% and AndroGel 1.62%?
›Is AndroGel safe for men with heart disease?
›Can AndroGel harm women or children in my household?
References
- Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-135. https://pubmed.ncbi.nlm.nih.gov/20554979/
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. https://pubmed.ncbi.nlm.nih.gov/26886521/
- AndroGel (testosterone gel) 1% and 1.62% Prescribing Information. AbbVie Inc. FDA label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021463s032lbl.pdf
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Arizona Revised Statutes § 36-3602. Telemedicine; definitions; requirements. Arizona State Legislature. https://www.azleg.gov/ars/36/03602.htm
- Drug Enforcement Administration. Telemedicine Prescribing of Controlled Substances, Temporary Extension. Federal Register 2023. https://www.fda.gov/news-events/press-announcements/dea-and-samhsa-extend-telemedicine-flexibilities-prescription-controlled-medications
- Arizona Revised Statutes § 20-3151. Prior authorization; requirements; timelines. Arizona State Legislature. https://www.azleg.gov/ars/20/03151.htm
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer. CA Cancer J Clin. 2010;60(2):70-98. https://pubmed.ncbi.nlm.nih.gov/20048681/
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. https://pubmed.ncbi.nlm.nih.gov/37326322/
- U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging. FDA.gov. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. https://pubmed.ncbi.nlm.nih.gov/29601923/
- Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836. https://pubmed.ncbi.nlm.nih.gov/24193080/
- Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108. https://pubmed.ncbi.nlm.nih.gov/23597181/
- Snyder PJ, Ellenberg SS, Cunningham GR, et al. The Testosterone Trials: seven coordinated trials of testosterone treatment in elderly men. Clin Trials. 2014;11(3):362-375. https://pubmed.ncbi.nlm.nih.gov/24776894/
- U.S. Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS): AndroGel. FDA.gov. https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm
- Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559. https://pubmed.ncbi.nlm.nih.gov/20525905/
- Centers for Disease Control and Prevention. Hypogonadism fact sheet and testosterone prescribing trends. CDC.gov. https://www.cdc.gov/nchs/products/databriefs/db458.htm